Stock Movers Intel Rises, Novo Higher and Cracker Barrel Falls on Earnings Miss
Sep 18, 2025
Intel's stock prices soar after a $5 billion investment from Nvidia for joint chip development. Novo Nordisk celebrates as its diabetes drug Ozempic outshines Eli Lilly's Trulicity in a real-world study. Meanwhile, Cracker Barrel faces a setback, lowering its revenue projections for fiscal 2026 due to disappointing traffic and rebranding challenges.
AI Snips
Chapters
Transcript
Episode notes
Nvidia-Intel Strategic Partnership
- Nvidia will invest $5 billion and co-design chips with Intel, signaling major industry collaboration.
- The deal triggered a ~25% intraday surge in Intel shares, its biggest jump since 1987.
Ozempic Shows Cardiovascular Benefits
- A real-world survey found Ozempic reduced heart attack or stroke risk by 23% among certain Medicare patients.
- The result lifted Novo Nordisk shares more than 6% despite the stock being down about 53% over 12 months.
Oral Pills Could Broaden The Market
- The next big expansion may come from oral versions of GLP-related medicines that broaden access and convenience.
- Oral pills could lower barriers like injections and cost, creating a second wave of patient adoption.